Investment Rating - The investment rating for the company is "Buy" [1]. Core Views - The company, Goldwind Technology, is a leading player in the domestic wind turbine manufacturing industry, with a significant increase in its wind farm development business contributing to new growth points [1][12]. - The company has maintained its position as the top player in the domestic wind power market for 13 consecutive years, with a market share of 20% in domestic new wind power installations in 2023 [1][20]. - The report anticipates steady growth in the company's performance, driven by robust traditional wind turbine sales and rapid expansion in wind farm development and services [4]. Summary by Sections 1. Deepening Wind Power Industry, Solidifying Leading Position - Goldwind Technology, established in 2001, has become a leading provider of wind power solutions in China and globally, with a continuous top market share in the domestic wind power market for 13 years [12][13]. - The company has a diversified business model, including wind turbine manufacturing, wind power services, and wind farm investment and development [12]. 2. Accelerating Wind Turbine Exports by Chinese Enterprises - The global wind turbine installation volume is expected to grow at a CAGR of 8.8% from 2023 to 2028, with record installations in 2023 [2][20]. - Goldwind Technology led the global market with 16.4 GW of new installations in 2023, maintaining its top position [24]. 3. Company Maintains Industry Leadership, Continuous Expansion of Wind Farm Development and Services - The company has a strong order backlog and has consistently ranked first in domestic market share for new installations [1][20]. - The profitability of the wind farm generation business is robust, with a recovery in gross margin for the wind farm development segment in 2024 [18][19]. - The company’s revenue from wind turbine and component sales has decreased from 82.93% in 2019 to 63.20% in 2024, while the wind farm development segment has increased from 7.14% to 21.79% [18].

2024 年 9 月 18 日 证券研究报告/公司研究 风电整机/风电设备/电力设备 金风科技 002202.SZ 国内风电整机龙头 风电场开发带来新增长点 主要观点： 基础数据： ◆金风科技以风机及零部件销售板块为传统主营业务，风电场开发业 截至 2024 年 9 月 18 日 当前股价 8.24 元 务占比提升。截至 2024 年 6 月末，风电及零部件销售板块收入占比从 投资评级 买入 2019 年的 82.93%下降至 63.20%，风电场开发板块占比从 7.14%提升 评级变动 首次 总股本 42.25 亿股 至 21.79%，主要是由于公司积极落地电站产品销售，将电站作为核心 流通股本 33.94 亿股 产品推动主营业务的持续增长。各板块毛利率方面，风机及零部件销 总市值 348 亿 售板块毛利率维持平稳，2023 年毛利率约为 6.41%；风电场开发板块 流动市值 280 亿 相对市场表现： 毛利率较高，2019-2022 年基本维持在 65%左右，2023 年下滑至 47.30%。主要是由于风电场开发板块包含电站产品和发电业务，无补 贴平价发电厂占比增加，电站产品毛利率较低，随建站规模增加，板 ...

Investment Rating - The investment rating for the power equipment industry is "Positive" and the rating has been maintained [3][5]. Core Insights - The power equipment industry index declined by 1.75% during the reporting period, outperforming the CSI 300 index by 3.13 percentage points [3]. - The cumulative decline of the power equipment industry from the beginning of 2024 to the end of the reporting period is 19.74%, which is 11.82 percentage points worse than the CSI 300 index [3]. - The report highlights the active market for onshore and offshore wind power, with significant project approvals and tenders that are crucial for future performance [5][6]. Market Review - The power equipment industry saw a mixed performance among its sub-sectors, with all six sub-sectors experiencing declines, particularly the photovoltaic equipment sector, which fell by 31.53% [3][13]. - Key tracked sub-sectors such as lithium batteries, wind power components, and battery chemicals also showed significant declines of -0.27%, -35.52%, and -38.12% respectively [3][13]. - The PE ratio for the power equipment industry is 23.06 times, which is below the negative one standard deviation and ranks 12th among the Shenwan first-level industries [3][26]. Industry Important News - The Shanghai Municipal Development and Reform Commission announced a list of 14 renewable energy projects for 2024, including 737.37MW of onshore wind and photovoltaic projects [30]. - In August 2024, 69 wind power projects were approved nationwide, totaling 12.47GW, with a majority being onshore projects [31][32]. - The report emphasizes the importance of project progress in the wind power sector for future earnings growth and suggests focusing on wind turbine and key component sectors [5][6][57]. Company Dynamics - During the reporting period, 12 listed companies in the power equipment industry experienced a net reduction of 623 million yuan in shareholder holdings, with 10 companies reducing their stakes [4][41]. - Notable company activities include a supply agreement for 19.5GWh of lithium iron phosphate batteries signed by a subsidiary of Yiwei Lithium Energy with AESI [39].

行业评级： 报告期：2024.9.2-2024.9.13 投资评级 看好 2024 年 9 月 18 日 证券研究报告 行业周报 huchenxi@gwgsc.com 执业证书编号：S0200518090001 联系电话：010-68085205 ◆商务部/国家卫健委/NMPA：在医疗领域开展扩大开放试点工作 ◆国家医保局/财政部：稳妥有序扩大跨省直接结算门诊慢特病病种 范围 weiyuqi@gwgsc.com 执业证书编号：S0200123060002 联系电话：010-68099389 ◆康诺亚：IL-4Rα抗体药物"司普奇拜单抗注射液（康悦达®）" 研究助理 魏钰琪 获 NMPA 批准上市，用于成人中重度特异性皮炎，为国内首款、全 球第二款 公司地址：北京市丰台区凤凰嘴街 2 号院 1 号楼中国长城资产大厦 16 层 ◆Candid Therapeutics：完成 3.7 亿美元融资，为今年规模最大的生物 医药融资 医药生物行业双周报 2024 年第 19 期总第 117 期 医疗领域开展扩大开放试点工作 多家药企临床数据亮相权威学术会议 行业回顾 评级变动 维持评级 本报告期医药生物行业指数跌幅为 4 ...

Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company maintains a leading position in the communication power grid sector, aligning with the development requirements of AI computing and communication. Its broadband products rank first in several procurement projects for major clients like China Mobile and China Tower [1][4] - The company has a robust order backlog of approximately 28.2 billion yuan, with significant contributions from various business lines, including marine, power grid construction, and renewable energy [2][4] - The company has achieved a notable increase in revenue and net profit in Q2 2024 compared to Q1 2024, indicating improved profitability despite a slight increase in expense ratios [1][4] Summary by Sections Financial Performance - For H1 2024, the company reported revenue of 21.416 billion yuan, a year-on-year increase of 6.32%, and a net profit attributable to shareholders of 1.460 billion yuan, a decrease of 25.31% [1] - In Q2 2024, the company achieved revenue of 13.174 billion yuan, a year-on-year increase of 11.00% and a quarter-on-quarter increase of 59.83%, with a net profit of 0.824 billion yuan, a quarter-on-quarter increase of 29.50% [1] Order Backlog and Business Development - As of August 27, 2024, the company has an order backlog of approximately 28.2 billion yuan, with marine projects accounting for about 12.3 billion yuan, power grid construction for about 13.1 billion yuan, and renewable energy for about 2.8 billion yuan [2][4] - The company has successfully delivered significant projects, including the first 330kV submarine cable project in China, and has made progress in international markets [4] Profitability and Expense Management - The company reported a gross profit margin of 16.68% and a net profit margin of 6.81% for H1 2024, with slight decreases compared to H1 2023 [1] - The expense ratio for H1 2024 was 9.09%, showing a manageable increase from the end of 2023, with specific expense ratios for sales, management, R&D, and financial expenses [1]

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The company reported a significant decline in revenue and net profit for the first half of 2024, with revenue at 7.038 billion yuan, down 47.57% year-on-year, and net profit at 493 million yuan, down 41.84% year-on-year [2] - The company is making steady progress in its global strategic layout, with a focus on increasing production capacity and expanding into overseas markets [2][3] - The negative electrode materials segment showed growth in shipment volume, with revenue reaching 5.179 billion yuan, an increase of 18.96% year-on-year, despite a decline in product prices [2] - The positive electrode materials segment faced challenges, with revenue of 1.587 billion yuan, a decrease of 50.30% year-on-year, primarily due to weaker overseas customer demand [3] - The company is actively pursuing product research and technological innovation, achieving a market share of approximately 70% in silicon-based negative electrode materials [3] Summary by Sections Financial Performance - For H1 2024, the company achieved a total revenue of 7.038 billion yuan, a decrease of 47.57% year-on-year, and a net profit of 493 million yuan, down 41.84% year-on-year [2] - The overall gross margin was reported at 21.26%, an increase of 0.27 percentage points compared to 2023 [2] Product Segments - Negative electrode materials generated revenue of 5.179 billion yuan, with a shipment volume exceeding 200,000 tons, reflecting an 18.96% year-on-year increase, although the average product price fell by over 20% [2] - Positive electrode materials saw revenue of 1.587 billion yuan, with a shipment volume of over 9,000 tons, down 50.30% year-on-year, and a gross margin of 5.98%, a decrease of 2.56 percentage points [3] Strategic Initiatives - The company has increased its production capacity for negative electrode materials to 495,000 tons per year and has launched new projects in Indonesia and Morocco to enhance its overseas presence [2][3] - The company is focusing on continuous product development and technological innovation, with successful large-scale industrialization of silicon-based negative electrode materials [3]

硅 基础数据： 鼎胜新材 603876.SH 2024 年 9 月 4 日 证券研究报告/公司研究 铝/工业金属/有色金属 电池箔盈利短期承压 有望受益海外市场高增长 截至 2024 年 9 月 4 日 事件：公司发布2024年半年度报告。2024年上半年，公司实现营业收 当前股价 8.96 元 入114.84亿元，同比增加24.57%；实现归母净利润1.84亿元，同比下降 投资评级 买入 47.60%；实现扣非归母净利润1.75亿元，同比下降42.52%；实现整体 评级变动 维持 总股本 8.90 亿股 毛利率9.88%，较2023H1下降了3.42Pct；实现整体净利率1.6%，较 流通股本 8.86 亿股 2023H1下降了2.20Pct。 总市值 79.72 亿元 流动市值 79.38 亿元 事件点评： 相对市场表现： zhangyetong@gwgsc.com 执业证书编号：S0200524050001 联系电话：010-68099390 ◆公司期间费用保持合理区间。2024H1，公司期间费用率为6.60%， 较2023H1下降了1.08Pct；其中销售费用为0.90亿元，同比下降12.60%； 管 ...

硅 事件点评： 基础数据： 截至 2024 年 9 月 4 日 事件：公司发布2024年半年度报告，2024H1公司实现营收52.80亿元， 当前股价 23.80 元 同比增长34.88%；实现归母净利润4.34亿元，同比下降46.92%；实现 投资评级 买入 扣非归母净利润3.88亿元，同比下降43.23%；实现整体毛利率16.59%， 评级变动 维持 总股本 12.26 亿股 环比2023H2提升了4.82Pct，较2023年年末下降了1.02Pct，较2023H1下 流通股本 1.88 亿股 降了8.02Pct。 总市值 292 亿元 流动市值 45 亿元 相对市场表现： 2024 年 9 月 4 日 证券研究报告/公司研究 风电整机/风电设备/电力设备 三一重能 688349.SH 风机交付创历史同期新高 ◆风机交付创历史同期新高，盈利能力环比改善明显。2024H1，公司 国内陆上风机交付容量3.3GW，同比增加121%，创造历史同期最好交 付业绩。公司上半年风机及配件实现收入49.17亿元，同比增长68.07%， 占总营收93.97%，其中，5MW及以上机组实现收入42.09亿元，同比增 长173. ...

硅 基础数据： 华宝新能 301327.SZ 相对市场表现： 分析师 张烨童 zhangyetong@gwgsc.com 执业证书编号：S0200524050001 联系电话：010-68099390 ◆公司不断深化全球品牌战略，加强全球渠道布局。2024H1，公司海 外销售实现营业收入10.73 亿元，占总营收93.89%，同比增长30.10%。 其中，公司坚定美国、日本市场持续开发投入和品牌构建，在美国市 场实现营收同比增长38.17%，日本市场实现营收同比增长51.13%，北 美市场实现销售6.45亿元，同比增长33.94%；亚洲（不含中国市场） 实现销售3.53亿元，同比增长52.57%。此外，为了进一步加强全球市 场的渗透，公司积极加强全球渠道的布局，通过官网独立站、第三方 电商平台和线下零售三位一体的渠道结合，公司产品累计热销超400万 台，全球销量领先。目前公司已在全球建立了21个官网独立站，业务 覆盖了全球50多个国家和地区。 zhugaotian@gwgsc.com 执业证书编号：S0200123030001 联系电话：010-68099392 2024 年 9 月 4 日 证券研究报告/公 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [4] Core Insights - The industry shows significant differentiation, with a focus on chemical preparations, raw materials, and CXO sectors [3] - In the first half of 2024, the total revenue of listed pharmaceutical and biotechnology companies in A-shares was 1.27 trillion yuan, a year-on-year decline of 0.28%, while the net profit attributable to shareholders was 104.32 billion yuan, a year-on-year decline of 2.11% [2][4] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index declined by 3.07% during the reporting period, ranking 27th among 31 primary industries, underperforming the CSI 300 index, which fell by 0.72% [4][12] - The PE ratio (TTM) for the industry as of August 30, 2024, was 23.12x, down from 23.99x, indicating a downward valuation trend [4][16] Performance Overview - In the first half of 2024, 455 tracked listed companies in the pharmaceutical and biotechnology sector reported their performance, with 48 companies achieving a net profit growth rate of 100% or more [2] - The chemical pharmaceutical, medical device, and traditional Chinese medicine sectors showed strong performance, with 88, 57, and 28 companies, respectively, reporting positive net profit growth [2][5] Investment Recommendations - The report suggests focusing on investment opportunities in innovative drugs, raw materials, and the CXO sector, as these areas have shown significant performance improvements [7]